Literature DB >> 15082595

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

L Benvegnù1, M Gios, S Boccato, A Alberti.   

Abstract

BACKGROUND AND AIMS: The natural history of initially compensated cirrhosis due to hepatitis B (HBV) or hepatitis C (HCV) virus is only partially defined. We have investigated morbidity and mortality rates and the hierarchy of complications in compensated viral cirrhosis over a long follow up period. PATIENTS AND METHODS: A cohort of Italian patients with initially compensated cirrhosis of viral aetiology were followed up at six monthly intervals with laboratory tests to identify major complications (ascites, gastrointestinal bleeding, portal-systemic encephalopathy, hepatocellular carcinoma) and to assess the progression of Child's stage and mortality rate due to liver related causes.
RESULTS: Between 1986 and 1996, 312 patients (43 HBV positive, 254 HCV positive, and 15 HBV and HCV coinfected) were included. During a median follow up of 93 (range 14-194) months, 102 (32.6%) patients developed at least one complication (HCV positive 31.1%; HBV positive 34.8%; HBV and HCV coinfected 53.3%). Overall, the most frequent complication was hepatocellular carcinoma which occurred in 65 (20.8%) cases, followed by ascites (61 cases, 19.5%), gastrointestinal bleeding (14 cases, 4.5%), and portal-systemic encephalopathy (six cases, 1.9%). Progression of Child's stage was observed in 62 patients (19.8%). Death from liver disease occurred in 58 (18.6%) cases and in 70.7% this was due to hepatocellular carcinoma. Hepatocellular carcinoma was the first complication to develop in 59 cases and represented the most frequent first complication in both HCV and HBV/ HCV related cirrhosis.
CONCLUSIONS: These results indicate significant morbidity and mortality during the first decade after diagnosis of compensated cirrhosis due to HBV and/or HCV, and identify hepatocellular carcinoma as the most frequent and life threatening complication, particularly in HCV positive cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082595      PMCID: PMC1774055          DOI: 10.1136/gut.2003.020263

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

Review 2.  Natural history of hepatitis C.

Authors:  A Alberti; L Chemello; L Benvegnù
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

Authors:  E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

4.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

5.  The long-term course of chronic hepatitis B.

Authors:  V Di Marco; O Lo Iacono; C Cammà; A Vaccaro; M Giunta; G Martorana; P Fuschi; P L Almasio; A Craxì
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

6.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

7.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

8.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

9.  The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Authors:  Y F Liaw; D I Tai; C M Chu; T J Chen
Journal:  Hepatology       Date:  1988 May-Jun       Impact factor: 17.425

Review 10.  Hepatitis B: evolving epidemiology and implications for control.

Authors:  H S Margolis; M J Alter; S C Hadler
Journal:  Semin Liver Dis       Date:  1991-05       Impact factor: 6.115

View more
  98 in total

1.  Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.

Authors:  Mazen Noureddin; Marc G Ghany
Journal:  Am J Gastroenterol       Date:  2010-10       Impact factor: 10.864

2.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

3.  Liver fibrosis assessment by transient elastography in hepatitis C patients with normal alanine aminotransferase.

Authors:  R Moreno-Otero; M Trapero-Marugan; J Mendoza
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

4.  Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B.

Authors:  Do Young Kim; Seung Up Kim; Sang Hoon Ahn; Jun Yong Park; Jung Min Lee; Young Nyun Park; Ki Tae Yoon; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2008-11-13       Impact factor: 3.199

5.  Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis.

Authors:  Baoxian Liu; Mengchao Wei; Furong Liu; Shuling Chen; Zhenwei Peng; Bin Li; Qian Zhou; Haibo Wang; Sui Peng; Ming Kuang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

6.  Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

Authors:  Yi-Cheng Chen; Chia-Ming Chu; Chau-Ting Yeh; Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-03       Impact factor: 6.047

7.  Clinical outcomes of compensated and decompensated cirrhosis: A long term study.

Authors:  Dimitrios N Samonakis; Mairi Koulentaki; Constantina Coucoutsi; Aikaterini Augoustaki; Chryssavgi Baritaki; Emmanuel Digenakis; Nikolaos Papiamonis; Maria Fragaki; Erminia Matrella; Maria Tzardi; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2014-07-27

8.  Comparison of liver biopsy and transient elastography based on clinical relevance.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Erik Goto; Takahisa Sato; Takamasa Ohki; Tadashi Goto; Hideo Yoshida; Fumihiko Kanai; Yosuke Sugioka; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

Review 9.  Chronic hepatitis C genotype 1 virus: who should wait for treatment?

Authors:  Cristiane Valle Tovo; Angelo Alves de Mattos; Paulo Roberto Lerias de Almeida
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

10.  Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease.

Authors:  Yoshitaka Kasai; Fuminori Moriyasu; Kazuhiro Saito; Takeshi Hara; Yoshiyuki Kobayashi; Ikuo Nakamura; Katsutoshi Sugimoto
Journal:  J Med Ultrason (2001)       Date:  2015-01-10       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.